These reports are not scientific evidence, but they do reflect real-world experience that can be informative when combined with the clinical data
Avoid pharmacies that cant provide verifiable license numbers
In the SURMOUNT-5 trial (comparing these drugs at weight-loss doses), more people discontinued semaglutide due to side effects (5.6%) than tirzepatide (2.7%)
When these factors are addressed first, GLP-1 therapy becomes part of a coordinated metabolic strategy rather than a stand-alone solution
Obesity contributes to the development and progression of Type 2 diabetes, a disease characterized by high blood sugar levels, insulin resistance, and a relative lack of insulin
This means the FDA does not review these drugs for safety, effectiveness, or quality before they are marketed